Therefore, it can be inferred that the therapeutic effect of UC-MSCs on NAFLD in db/db mice was associated with the upregulation of the HNF4α-CES2 pathway. The gene discussed is CES2; the disease is metabolic dysfunction-associated steatotic liver disease.